Cipla launches Nintib to treat Idiopathic Pulmonary Fibrosis Kumar Jeetendra | October 20, 2020 Mumbai, India; October 20, 2020: Cipla Limited (BSE: 500087; NSE: CIPLA EQ; and hereafter referred to as “Cipla”) today announced that it has launched generic Nintedanib for the treatment of Idiopathic Pulmonary Fibrosis (IPF). Available as 100 mg and 150 mg capsules, it will be marketed under the brand name Nintib. This launch marks yet …